Nanomedicine in cerebral palsy

Bindu Balakrishnan\(^1\)
Elizabeth Nance\(^1\)
Michael V Johnston\(^2\)
Rangaramanujam Kannan\(^3\)
Sujatha Kannan\(^1\)

\(^{1}\)Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University; Baltimore, MD, USA; \(^{2}\)Department of Neurology and Pediatrics, Kennedy Krieger Institute, Baltimore, MD, USA; \(^{3}\)Department of Ophthalmology, Center for Nanomedicine, Johns Hopkins University, Baltimore, MD, USA

Abstract: Cerebral palsy is a chronic childhood disorder that can have diverse etiologies. Injury to the developing brain that occurs either in utero or soon after birth can result in the motor, sensory, and cognitive deficits seen in cerebral palsy. Although the etiologies for cerebral palsy are variable, neuroinflammation plays a key role in the pathophysiology of the brain injury irrespective of the etiology. Currently, there is no effective cure for cerebral palsy. Nanomedicine offers a new frontier in the development of therapies for prevention and treatment of brain injury resulting in cerebral palsy. Nanomaterials such as dendrimers provide opportunities for the targeted delivery of multiple drugs that can mitigate several pathways involved in injury and can be delivered specifically to the cells that are responsible for neuroinflammation and injury. These materials also offer the opportunity to deliver agents that would promote repair and regeneration in the brain, resulting not only in attenuation of injury, but also enabling normal growth. In this review, the current advances in nanotechnology for treatment of brain injury are discussed with specific relevance to cerebral palsy. Future directions that would facilitate clinical translation in neonates and children are also addressed.

Keywords: dendrimer, cerebral palsy, neuroinflammation, nanoparticle, neonatal brain injury, G4OH-PAMAM

Cerebral palsy: scope of the problem

Cerebral palsy (CP) is a chronic childhood disability with no effective cure; it results in a significant personal, social, and economical burden. CP was first described by an orthopedic surgeon William John Little in 1862, who noted that newborns who underwent asphyxia or mechanical injury before or during childbirth developed rigidity and distortion of limbs later in life.\(^1\) Initially, CP was considered solely to be a movement disorder associated with white matter injury, mainly because the characteristic signs observed in these patients are abnormalities in movement and coordination that include spasticity, rigidity, ataxia, and muscle weakness.\(^2\) However subsequent studies have shown that apart from white matter injury, grey matter abnormalities in the cortex and subcortical structures contribute to developmental delays, cognitive disturbances, and psychomotor abnormalities in these patients.\(^3,4\) To include these symptoms, CP is now more comprehensively defined as a “group of permanent disorders of the development of movement and posture, causing activity limitation that is attributed to nonprogressive disturbances that occurred in the developing fetus or the infant brain. [These] are often accompanied by disturbances of sensation, perception, cognition, communication and behavior.”\(^7\)
Cerebral palsy is the most common cause of childhood disability. The US Centers for Disease Control and Prevention (CDC) has reported a worldwide prevalence of 1.5–4 per 1,000 live births, with an average lifetime cost of ~1 million dollars per person in the US. The autism and developmental disabilities monitoring network conducted a surveillance of CP among 8-year-old children and reported a prevalence of 3.3 per 1,000 children, with a male/female ratio of 1.4:1. The incidence of CP is strongly associated with gestational age, and prematurity is considered to be a leading risk factor for the development of CP. Even though technological advancements in neonatal intensive care units have resulted in improved survival of premature and very low birth weight infants, the incidence of CP has not decreased. Whereas 5%–10% of premature infants develop motor disability, a much larger proportion (40%–50%) develop some form of cognitive and/or behavioral abnormality. However, there is at present no cure for perinatal/neonatal brain injury and CP. Neuroprotective strategies such as therapeutic hypothermia, which is currently considered to be the most promising approach to improved outcomes, results in only an 11% decrease in risk of death or severe disability. Patient management is primarily confined to methods of rehabilitation for alleviating symptoms and improving quality of life. Despite these advances, decreasing the incidence of CP will not be possible until new treatments for the disorder can be discovered.

Several risk factors, such as very low birth weight, prematurity, intraventricular hemorrhage, multiple pregnancy, chorioamnionitis, hypoxia, neonatal encephalopathy, fetal infections, and genetic factors, have been found to be strongly associated with CP. The primary pathophysiological mechanisms that result in CP can be broadly classified as: (1) hypoxia and ischemia that leads to a cascade of excitotoxic events in the brain; (2) intrauterine infections/inflammation resulting in a fetal inflammatory response syndrome and neuroinflammation; and (3) genetic or other congenital causes. These mechanisms may often work in combination. Although CP can have multiple etiologies, neuroinflammation and periventricular leukomalacia (PVL) are common pathological substrates. Inflammation in the central nervous system (CNS) is mediated by immune cells in the brain that include microglia and infiltrating macrophages. Activated microglia and astrocytes are implicated in the development of a number of neurodegenerative disorders both in children and adults. Periventricular leukomalacia, the pathophysiological substrate associated with CP in humans, is characterized by focal necrosis around the ventricles, and diffuse microglial and astrocyte activation in the immature white matter.

**Glial activation and neonatal brain injury**

Microglia and astrocytes, the two major glial cells in the brain, play a pivotal role in CNS injury and repair. Of the two, microglia are crucial for remodeling and growth in the developing brain. During the process of human fetal development, microglia are present along the white matter tract from late second trimester onward and perform a supportive role in myelogenesis and axonogenesis. Though the primary function of microglia during development is to provide a supportive role, their presence can accentuate the vulnerability of the developing brain to various brain insults.

Activated microglia/macrophages play a key role after CNS injury and can be either protective or detrimental. However, the microglial/macrophage response may depend on the type (infection/inflammation versus hypoxic ischemia) and the timing of injury (acute versus chronic). Suppressing the immediate microglial response after an hypoxic-ischemic insult in a neonatal stroke rat model has been shown to be deleterious. However, a proinflammatory activation of these cells can result in an exaggerated, ongoing inflammatory response that persists long after the injury, with formation of free radicals, excitotoxic metabolites, and proinflammatory cytokines, leading to diffuse white and grey matter injury as seen in CP. In severe inflammation, astrocytes that normally participate in the protection of neurons and in preventing oxidative injury, are unable to maintain their neuroprotective role. An increased number of activated microglia have been noted along the white matter tract in autopsy specimens of patients with PVL. In response to an immune activation, microglial cells and astrocytes in the fetal and newborn brain can secrete cytokines such as IL1β and TNFα, causing injury to developing oligodendrocytes and neuronal progenitors. Similarly, studies have demonstrated the presence of hypertrophic astrocytes in kittens and fetal sheep following LPS injection. Diffuse astrogliosis is a major pathological feature in white matter injury and is associated with arrest of oligodendrocyte maturation. Similarly, we have shown that intrauterine administration of lipopolysaccharide leads to intense proinflammatory microglial activation in the periventricular region of the fetal brain that corresponds with the extent of motor deficits in the neonatal rabbit.

There is a growing body of literature to suggest that strategies to target neuroinflammation can potentially...
Nanomedicine in cerebral palsy

Dendrimer nanodevices for the treatment of cerebral palsy

CP has always been a challenging neurological disorder for development of therapies because of the multifocal nature of the brain injury and the difficulty in early diagnosis unless symptoms are very severe. However, recent studies have shown that neuroinflammation associated with perinatal brain injury can be detected by serum biomarkers that persist even after birth, or by imaging using positron emission tomography (PET) to noninvasively detect persistent activated microglia in the brain.\(^{53,54}\) Our recent studies in rabbit kits with CP born to mothers administered intrauterine endotoxin revealed the significant potential for nanomedicine approaches in this challenging disorder that has no effective cure.\(^{42,55}\)

When G4OH-PAMAM dendrimers were administered intravenously to newborn rabbits with CP, the dendrimers crossed the BBB and selectively localized in cells associated with neurodegenerative diseases.\(^{39–42}\) Therefore, an approach that attenuates neuroinflammation in a targeted manner may be beneficial in treating perinatal brain injury, improving brain development and motor function in CP. However, treatment of disorders such as CP is challenging because (1) inflammation and injury are often diffuse in the white matter, precluding local brain delivery; (2) postnatal treatment of a prenatal injury to the brain is not expected to result in improvement in motor function; and (3) transport of drugs across the blood–brain barrier (BBB) is often difficult to achieve. An ideal therapeutic agent targeted to the brain should have minimal systemic effects; should be able to cross the BBB only in the presence of injury; and must exert its effect specifically in the cells involved in injury. A critical balance of all these characteristics would be required for the therapeutic to be effective in clinical trials. Moreover, since CP is a clinical diagnosis that is often made later in life, early treatment would be directed to ‘at-risk’ patients. Hence a therapeutic agent that has minimal side effects and is not effective when there has been no insult to the brain would be most likely to be clinically translated.

Nanoparticles for the treatment of brain injury

Despite the advances in CNS therapies and increasing understanding of disease origin and progression, treatment of CNS diseases remains a significant challenge. There is a paucity of studies exhibiting evidence of a critical correlation between early detection, prognosis, and treatment success. Nanotechnology-based approaches are providing potential platforms for CNS therapy. The physicochemical properties of the nanoparticles can be tailored to overcome the BBB\(^ {45}\) and to improve penetration and diffusion through the brain parenchyma,\(^ {44}\) allowing for controlled, sustained release of a therapeutic. These approaches have shown significant promise in preclinical studies for the treatment of many CNS diseases, including cancer, neuroinflammation, and neurodegeneration. Among the different nanoparticle platforms, dendrimers show significant promise as drug delivery vehicles due to their small size, tailorable end groups, and favorable biosafety profile.

Dendrimers as drug delivery vehicles

Dendrimers, soft globular molecules about 3–10 nm in size, are emerging as promising candidates for diagnostic platforms and targeted drug and gene delivery vehicles (Figure 1). Recently, promising efficacy results have been reported in preclinical studies, including cancer, systemic inflammation and rheumatoid arthritis.\(^ {45–48}\) The small size, branching architecture, and high density of tailorable surface functional groups can provide significant advantages for CNS and BBB transport. Polyamidoamine (PAMAM) dendrimers are widely studied due to their commercial availability. The growing interest in the PAMAM dendrimer as a vehicle for drugs is mainly attributable to the ability of the nanoparticle to enhance the selectivity and stability of the drug. In vivo administration of PAMAM dendrimer grafts attached to the anticancer drug 5-fluorouracil (5-FU) in rats has shown to increase its bioavailability compared with the free drug.\(^ {49}\) The efficacy of nonsteroidal anti-inflammatory drugs such as indomethacin has been shown to be enhanced by conjugation of the drug with folic acid-coupled dendrimers in a rat model of arthritis.\(^ {50}\) Cell-specific internalization of a dendrimer-drug conjugate has been reported to overcome the resistant action of P-glycoprotein in tumor cells. Kukowska-Latallo et al\(^ {51}\) have reported that when acetylated dendrimer conjugated with folic acid and coupled with methotrexate was injected into immunodeficient mice bearing tumor cells, there was increased uptake of drug into tumor-specific cells. Poly(ethylene glycol)-lysine dendrimers have been used as a carrier to deliver nitric oxide to alleviate the symptoms of atherosclerosis.\(^ {52}\)Recent studies by Iezzi et al and Kannan et al have shown that hydroxyl-functionalized PAMAM dendrimers can target neuroinflammation in the retina upon intravitreal administration and provide sustained neuroprotection for at least 30 days through targeted, intracellular delivery of a steroid.\(^ {53}\)
neuroinflammation. This selective localization into activated microglia and astrocytes was seen in CP kits, with minimal brain uptake and localization shown in healthy kits. To take advantage of this selective localization, we coupled N-acetyl cysteine (NAC) to these dendrimers, and engineered them for tailored intracellular release. NAC has both antioxidant and anti-inflammatory properties, and is widely used clinically in children and adults; it is being evaluated in several clinical trials. Improved delivery and efficacy with a safe drug, already in clinical use for other applications and undergoing clinical trials for neuroinflammatory disorders, provides an easier path to translation.

For dendrimer-NAC conjugates, the NAC is released from dendrimer in a glutathione (GSH)-dependent manner in the cells, decreasing the inflammatory response, decreasing microglial and astrocyte activation, and improving white matter injury in the kits (Figure 2). Four days after intravenous administration of D-NAC, there was a dramatic improvement in motor function of CP kits, which was associated with significant improvement in neuronal injury, myelination, oxidative injury, and inflammation (Figure 3). When NAC was conjugated to the dendrimer, it was 10- to 100-fold more effective than in its free form. More importantly, these studies suggest that targeted, timely, postnatal attenuation of a prenatal brain injury can be effective. NAC is normally used in very high doses because of the poor bioavailability resulting from protein binding of its –SH groups. Moreover, L-cysteine has been shown to have neurotoxic effects, resulting in neuronal death from overactivation of NMDA receptors on neurons. Inflammation also causes depletion of GSH in astrocytes, with a loss of their normal neuroprotective role. We expect that delivery of NAC specifically to activated astrocytes and microglia will result in suppression of neuroinflammation and oxidative stress along with replenishment of GSH in astrocytes, thereby leading to sustained improvement of myelination, reduction of white matter injury, and improved neurobehavioral outcomes in neonatal mice and rabbits with PVL. Hence, selective delivery of NAC to glial cells may help decrease neuronal toxicity.

Intraventricular and intraparenchymal injection of cationic G4-NH2 dendrimers has shown that dendrimers diffuse into the brain parenchyma and are endocytosed into specific compartments of neurons and microglia. The capacity of the G4 dendrimer to be internalized into the neurons and activated glial cells reveals the intrinsic behavior of this nanocarrier and its therapeutic potential in the field of nanomedicine for neurological disorders.

A summary of recent preclinical studies involving nanoparticle-based therapies for neuroinflammation and neurodegenerative disorders is provided in Table 1. Most of the studies have involved animal models of adult neurodegenerative disorders using nanoparticles that have typically ranged in size from 5–100 nm. Pediatric neurological disorders have typically not been a focus of the studies. Therapeutic nanoparticles used in preclinical neuro-oncology studies has been extensively covered in two recent reviews. Unfortunately, even though many nanomedicine platforms have shown success in preclinical studies, there are no clinical trials that the present authors are aware of that incorporate the use of nanoparticles for the treatment of CNS diseases other than CNS tumors or malignancies, as indicated in Table 2.

Apart from maternal inflammation, hypoxia-ischemia is one of the major causes of perinatal and neonatal brain injury resulting in CP. Therefore, therapies that have been effective in adult models of stroke, or in adult neuroinflammatory or neurodegenerative disorders such as Alzheimer’s, or multiple sclerosis, could also have potential benefits for treatment of neonatal brain injury. Poly(ethylene glycol)-coated chitosan nanospheres that were functionalized with transferrin receptor monoclonal antibody for transportation across the BBB and loaded with N-benzyloxycarbonyl-Asp(OMe)-Glu(OMe)-Val-Asp(OMe)-fluoromethylketone (Z-DEVD-FMK), a relatively specific caspase-3 inhibitor, resulted in decreased infarct size, along with functional improvement in an adult animal model of stroke, when administered...
intravenously either as a pretreatment or within 2 hours after injury.\textsuperscript{44} e-PAM-R, a biodegradable arginine ester of G4OH PAMAM dendrimer, was effective in transfection of high
mobility group box-1 (HMGB1) in neurons and astrocytes, and was neuroprotective when administered intracranially as a pretreatment prior to the insult.\textsuperscript{45} Intraperitoneal
administration of lipid core nanocapsules loaded with drugs such as indomethacin or resveratrol resulted in decreased expression of activated microglia and proinflammatory cytokines in a rat model of Alzheimer’s disease. Although the actual presence of the lipid core nanocapsules was not demonstrated in the brain, an increased concentration of

---

**Figure 2.** Diagrammatic representation of D-NAC treatment in rabbit kits with CP.

**Notes:** Maternal intrauterine infection/inflammation by LPS treatment results in increased proinflammatory cytokines, leading to activated microglia and astrocytes in the fetus. The activated glial cells further secrete proinflammatory cytokines and free radicals, resulting in oxidative injury, maturation arrest of premature oligodendrocytes, and white matter injury. Intravenous administration of D-NAC in CP kits on postnatal day 1 results in uptake of the dendrimer drug conjugates by activated microglia and astrocytes. Once inside the glial cells, NAC increases the GSH level, decreasing the release of proinflammatory cytokines and synthesis of free radicals with restoration of myelination by oligodendrocytes. Thus D-NAC treatment ameliorates the motor deficits in rabbit kits with CP.

**Abbreviations:** D-NAC, dendrimer-N-acetyl cysteine; CP, cerebral palsy; LPS, lipopolysaccharide; GSH, glutathione; TNF, tumor necrosis factor; IL, interleukin; NAC, N-acetyl cysteine.
the drug was demonstrated in the brain tissue. Several of these therapies have focused on pretreatment or treatment immediately after the injury, which may not be clinically relevant in the treatment of perinatal or neonatal brain injury resulting in CP, as the injury often occurs in utero and before birth. However, because the pathophysiology involving activated microglia and inflammatory cytokines resulting in hypomyelination and axonal loss, may have similarities, some of these therapies may have potential applications in the treatment of CP.

**Therapeutic window and clinical considerations**

Although CP is considered to be nonprogressive, the developing brain continues to undergo changes based on the developmental stage, to adapt to the injury. This may be dictated by ongoing inflammation in the brain, as evidenced by preclinical studies and postmortem studies in humans with periventricular leukomalacia that shows persistent, diffuse astro- and microgliosis along the periventricular region of the brain. Positron emission and postmortem studies in traumatic brain injury have demonstrated activation of microglia in the thalamus several years after injury. Persistent activation of microglia has been observed in other neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease, and multiple sclerosis. Animal studies have also demonstrated persistence of inflammation for at least one year after the initial insult. This suggests that the window of opportunity for therapeutic intervention may be much longer than is usually considered.

Impairment of the BBB appears to facilitate increased accumulation of the dendrimer in the brain. Although the neonatal BBB has been shown to be well-developed, similar to that in the adult brain, the presence of an injury can result in impairment of the BBB. The degree of leakage through the BBB can be variable, and may depend on the type of disease,
the developmental age and timing from the insult. Since ongoing inflammation is often associated with increased BBB permeability resulting from formation of matrix metalloproteinases, this impairment may also persist after the initial insult. In the presence of neuroinflammation or injury resulting in BBB impairment, leakage of intravenously administered gadolinium contrast in the brain parenchyma in an infant at 8 days after a hypoxic ischemic insult, indicating that the BBB impairment may persist for days or even weeks after the original insult, potentially extending the therapeutic window. Microglial cells can have both protective and harmful roles; hence, the time point at which microglial activation is suppressed may be crucial for dictating the response. It is possible that the initial microglial response may involve pro- and anti-inflammation, with a peak proinflammatory response that occurs later.

Table 1 Preclinical studies using nanoparticles for therapeutic delivery for neuroinflammation and neurodegeneration

<table>
<thead>
<tr>
<th>Disease model</th>
<th>Nanoparticle platform</th>
<th>Administration route</th>
<th>Main conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alzheimer’s</td>
<td>Curcumin delivery by polymeric nanoparticle</td>
<td>Intraperitoneal</td>
<td>NanoCurc can ameliorate reactive oxygen species-mediated damage</td>
</tr>
<tr>
<td></td>
<td>Oral</td>
<td>Oral administration resulted in significant improvements in working and cue memory</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Piperine delivery by solid lipid nanoparticles</td>
<td>Intraperitoneal</td>
<td>SLN coated with P80 shows therapeutic effect through reduced oxidative stress</td>
</tr>
<tr>
<td></td>
<td>Indomethacin delivery by solid lipid nanoparticles</td>
<td>Intraperitoneal</td>
<td>SLN attenuated cell death and suppressed microglial activation</td>
</tr>
<tr>
<td></td>
<td>Carbon nanotube delivery of acetylcholine</td>
<td>Gastrogavage</td>
<td>Therapeutic effect due to delivery of acetylcholine into neuronal lysosomes</td>
</tr>
<tr>
<td>Parkinson’s</td>
<td>NGF delivery by P80 coated PBCA nanoparticle</td>
<td>Intravenous</td>
<td>Reduction of oligokinesia, rigidity, and tremor</td>
</tr>
<tr>
<td></td>
<td>Urocortin delivery by PLGA-PEG</td>
<td>Intravenous</td>
<td>Attenuation of striatum lesion</td>
</tr>
<tr>
<td></td>
<td>Aromorphine delivery by solid lipid nanoparticles</td>
<td>Intravenous</td>
<td>Functional and behavioral recovery obtained</td>
</tr>
<tr>
<td></td>
<td>GDNF delivery by PEGylated dendrimers</td>
<td>Intravenous</td>
<td>Better therapeutic efficacy for behavioral recovery</td>
</tr>
<tr>
<td></td>
<td>GDNF delivery by immunoliposomes</td>
<td>Intravenous</td>
<td>Improved locomotor activity, reduction of neuronal loss and enhanced neurotransmitter level</td>
</tr>
<tr>
<td>Multiple sclerosis or ALS</td>
<td>Fullerenes</td>
<td>Intraperitoneal</td>
<td>Reduction of MS progression by decrease in axonal and myelin loss</td>
</tr>
<tr>
<td>Cerebral palsy</td>
<td>NAC delivery by PAMAM dendrimers</td>
<td>Intravenous</td>
<td>NAC conjugated dendrimers suppress neuroinflammation and improve motor function in CP rabbits</td>
</tr>
<tr>
<td>Ischemia/stroke</td>
<td>Hemoglobin delivery by liposome</td>
<td>Intraparenchymal</td>
<td>Suppression of infarct areas in rats with stroke</td>
</tr>
<tr>
<td></td>
<td>VEGF delivery by immunoliposomes</td>
<td>Intravenous</td>
<td>Decreased infarct volume and promotion of neurovascularization</td>
</tr>
<tr>
<td></td>
<td>Carbon nanotubes</td>
<td>Intraventricular</td>
<td>Protection of neurons and enhanced motor neuron function</td>
</tr>
<tr>
<td></td>
<td>siRNA delivery by PAMAM dendrimers</td>
<td>Intraparenchymal</td>
<td>Infarct formation suppression in post-ischemic brain with pretreatment</td>
</tr>
<tr>
<td></td>
<td>Chitosan PEG-nanospheres</td>
<td>Intravenous</td>
<td>Neuroprotection by delivery of anti-caspase peptide in stroke with pre-treatment and immediately after injury</td>
</tr>
<tr>
<td></td>
<td>Fullerene</td>
<td>Intravenous and intraventricular</td>
<td>Suppression of cerebral infarction volume and attenuation of oxidative injuries</td>
</tr>
<tr>
<td></td>
<td>Nitroxyl radical delivery by core-shell micelles</td>
<td>Intracarotid</td>
<td>Reduced infarct volume by 65%</td>
</tr>
<tr>
<td></td>
<td>Reduced superoxide anions in neuronal cells and infarction volume</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Traumatic brain injury</td>
<td>PEGylated silica nanoparticles</td>
<td>Intravenous</td>
<td>Spinal cord conduction recovered</td>
</tr>
<tr>
<td></td>
<td>Carbon nanotube functionalized with PEG</td>
<td>Intraspinal</td>
<td>Some improvement in hind-limb locomotor function</td>
</tr>
<tr>
<td>Epilepsy</td>
<td>Phenytoin delivery by liposomes</td>
<td>Intravenous</td>
<td>Reduced penicillin induced epileptic activity</td>
</tr>
</tbody>
</table>

Abbreviations: NanoCurc, curcumin nanoparticles; siRNA, small interfering ribonucleic acid; SLN, solid lipid nanoparticles; NGF, nerve growth factor; P80, polysorbate-80; PBCA, poly(butyl cyanoacrylate); PLGA-PEG, poly(lactic-co-glycolic acid-poly(ethylene-glycol)); GDNF, glial cell line-derived neurotrophic factor; MS, multiple sclerosis; ALS, amyotrophic lateral sclerosis; PAMAM, polyamidoamine; NAC, N-acetyl cysteine; CP, cerebral palsy; VEGF, vascular endothelial growth factor; PEG, poly(ethylene glycol).
CP, at 3 days after the injury, leads to improved neurological outcomes in the short term. In that study, the therapeutic intervention occurred later in the postnatal period, after the injury had occurred, at time points when there was ongoing inflammation. Nanoparticle uptake and delivery of therapeutic agents into the cells may also be influenced by the microglial phenotype and function during different stages of the disease. All these features will have to be carefully considered when designing therapies for brain injury in CP. We have previously shown that the hydroxyl terminated dendrimers are taken up intracellularly by active pinocytosis. It is possible that activated microglia have a greater phagocytic and/or pinocytic capacity that allows them to selectively take up the dendrimers. Future studies to elucidate the specific processes involved in dendrimer uptake by the activated microglia would be crucial in further optimizing the drug delivery nanodevice.

### Biosafety and toxicity studies for nanoparticle platforms

As the therapeutic field of nanotechnology steadily advances, a detailed evaluation of nanoparticles in vivo is essential to address the issues of biosafety and toxicity of these particles. Multiwalled carbon nanotubes injected into pregnant mice have been shown to result in teratogenic effects in the embryo, and cationic amine terminal G4 dendrimers were found to be toxic in developing zebra fish embryos. To maintain a balance between maximum therapeutic efficacy and reduced toxicity in the developing brain, it is essential to determine the dose, type of nanoparticle, and route of administration. We have shown that administration of 550 mg/kg of G4OH PAMAM dendrimer, which is 10 times the dose used in the efficacy studies, did not demonstrate any toxic effects in newborn rabbits. It is likely that the presence of the neutral -OH groups on the dendrimer surface may be responsible for the increased safety profile in these animals. However, further studies in larger animals would be important to establish the biosafety profile of the hydroxyl-terminated dendrimers for prenatal and postnatal treatment.

### Future directions

An ideal therapeutic strategy would not only involve suppression of inflammation and injury but also promote regeneration and repair. Because several mechanisms such as inflammation, excitotoxicity, and oxidative injury con-
Nanomedicine in cerebral palsy

Figure 5 Potential future nanotherapeutic approaches in cerebral palsy.
Notes: Dendrimer-based drug delivery to pregnant mothers with infection/inflammation may reduce inflammatory response in the mother and the fetus. Prenatal therapies may involve systemic treatment of the mother to modulate the maternal immune response and/or treatment of the fetus by intra-amniotic administration of the nanodevices. Postnatal therapies would involve treatment of ongoing injury after birth. Therapies may potentially involve use of stem cells in combination with drugs or after modification by nanoparticles to promote differentiation; delivery of trophic and growth factors, or delivery of combination therapies using nanoparticles.

In tribute to the brain injury, combination therapies delivered to the brain that target multiple pathways would provide the maximum benefit. When these therapies are combined with approaches to promote regeneration, such as delivery of growth factors and stem cells, it may be possible to achieve normal brain development and functioning for a disorder that currently has no therapies available. Presence of risk factors for CP, such as chorioamnionitis, maternal fever, perinatal asphyxia, intraventricular hemorrhage, persistence of serum inflammatory biomarkers after birth, and neonatal white matter abnormalities that are well characterized in several epidemiological studies, will help in the early identification of infants who would benefit from such therapies soon after birth or even in utero. Prenatal therapy that is directed toward regulating the maternal inflammatory response and/or fetal inflammation may also provide therapeutic strategies that can prevent brain injury in at-risk patients (Figure 5). We have previously shown that G4-OH PAMAM dendrimers do not cross the normal human placenta. This feature could be exploited for tailoring the treatment to the maternal and fetal compartments. We would anticipate that systemic therapies administered to the mother would remain in the maternal compartment and could be leveraged to modulate the maternal immune response, hence indirectly changing the fetal immune response. Similarly, administration of the dendrimer nanodevices in the amniotic fluid can be a potential route of prenatal treatment for prevention of perinatal brain injury. Postnatal therapies can be further refined by a mul-
tripronged approach that would attenuate several pathways involved in inflammation, through combination therapies and by coadministering trophic factors and/or stem cells that would promote repair and regeneration. Several in vitro studies have demonstrated the feasibility of modifying stem cells with nanoparticles that include dendrimers.\textsuperscript{135-138} Stem cells that have been modified to promote differentiation that is individually tailored for the type of injury has the potential to aid treatment of older patients with cerebral palsy.

**Acknowledgment**
The authors thank Dr Amar Jyoti for the astrocyte images.

**Disclosure**
The authors report no conflicts of interest in this work. This work was supported in part by R01 HD069562, NICHD, NIH.

**References**


